Benzinga | Nov 4, 2021 06:27AM EDT

HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $62

HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $58 to $62.